Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Blue - I would have argued with you about what you just said a month ago. But with what I have recently learned, you might be right.
Numbers - me and you are roughly in the same ballpark where the numbers roughly are. The company looked at Bloombergs numbers and said they could find no correlation to them that made sense. So I am not sure everything you said is right, but I do agree that the ipci q4 seroquol revenue will only be a couple hundred thousand.
Angelo - my point is that Mnk did not sell anywhere near $5M of seroquol xr in 4Q. Please if you do not believe me contact ipci and they will confirm those $ amounts from Bloomberg are inaccurate.
Angelo - I bet if you take the time to run those numbers past ipci for seroquol, they will tell you they are way too and not accurate. Please do it. I did and they said they are wrong.
Impact- What area of the US or Canada did the call come out from?
Impact- I am going to stop the negative talk. I will cut them at least 3-6 months of slack to see if we can get things turned around.
mopar- From what I heard about Odidi this week, some of my assumptions, speculations, interpretations about him may have been wrong. Sounds like he is proud of the company and was very open to share as much as he could. Shorts live off of misinformation. That being said, I don't think too many people have been shaken out lately. Maybe a few traders but it seems most investors have held strong.
Mike- I agree. My hats off to everyone that went to meet with management. Thanks for all your efforts. I need to get there one day as well.
Fabius- I do see your point. One thing I think is not many shares are changing hands. I think they are the same shares wash traded over and over. These guys that are doing it do not want to lose shares when they walk it down. When there are real orders in, they will sit just above the real orders for days and wash trade above them even by as little as 1/10 of a cent. I have witnessed this many times. They can't afford to lose the shares. But eventually those real orders do get filled. If there are no real orders in the way, they can walk down as far as they want.
Mopar- I agree that conference calls will be a big plus. It will keep everyone informed and stop the misinformation.
Beach- I think last earnings they pushed out CFP status until mid 2018. I am guessing we hear update this next earnings report. But if you really want to know, give them a call and ask them directly.
Beachguy- I cannot answer your question but I will tell you what I think is an important first step. That is getting to CFP status with the threat for further dilution(just to keep doors open) off the table. I think most were expecting this by now- but it has gotten delayed. I think that will the first step in a multi step process. After that, I would expect only a real development to take this stock to the next level. By real development, I am not talking about an ANDA approval or commercialization of more ANDAs. I am talking about something that shows the NDA candidates are close to generating revenue or good test data on PODRAS or another game breaking technology.
All- I really think what we are seeing with the price action is uncertainty about another offering. Let's face it- MNK just did not deliver getting Seroquel contracts early and sales numbers are bad until they can claim some of these contracts. So What I think people are worried about is another offering early or mid next year. A couple things that could help alleviate some of this anxiety:
1. Markedly improved Seroquel numbers. I am getting the impression this is a few months out though.
2. Cash infusion from partnership.
3. Approval of Pristiq or Lamictal. These could be commercialized relatively quickly and add to bottom line in a few months.
That is what I see and would like hearing others opinions.
Great! Thanks Impact
Impact- a video could be made to show they are a real company, with real employees, that are doing research, testing, manufacturing, etc. You get my picture. Show their facility. Show their employees, talk to the leaders, etc.
Impact- You should go in and film a video for them and get the word out. It will be a nice break from all the adult videos you have been producing in Vegas lately, LOL
Mike- I will meet you in July if you would like that. I found:
2018 U.S. Open July 28-August 5
Madison Marriott West
Middleton, WI 53582
(888) 745-2032
I work not far from the Marriott.
Mike- I am located in Madison area, so not too far from you. Probably about 2 hours.
Angelo- Before you said 20K shares of IPCI will make you a millionaire. Today I say 20K shares of IPCI gives you a lifetime supply of toilet paper! LOL
Doog and Mike- IPCI's new motto: Everything that can go wrong will! LOL
Mike- Are you from Ozaukee County? What city do you live in?
Fabius- We now roughly need a 300% gain to get back to pre-Adcom levels...
It appears to me all the odidis care about is getting patents. They have done nothing to suggest they give a damn whether products are commercialized or the company is profitable.
Mike - I looked at those two trades and my conclusion was they were both wash trades. They moved the pps about a penny, so you be the judge.
Samsa- With all the products they have in the pipeline and potential products... Shouldn't they always be negotiating deals? Oh wait, this IPCI, they don't negotiate on anything! Never mind! LOL...
Fabius- Yes, I have let Mr. Odidi know personally that I don't think he is getting the job done. Any other shareholder that feels the same should as well.
The last time I talked to Penna he said his departure had absolutely nothing to do with Rexista adcom. He said he still had a strong belief the Rexista ADF technology was best in class.
Doog- I will tell you why that CNN story as well as the interview from February 2017 might have vanished. I personally sent Odidi and his wife a couple emails pointing out that we have heard nothing since his February 2017 interview. Here is one of them:
Dr. Odidi,
You gave the following interview in February of 2017:
https://www.midasletter.com/2017/02/intellipharmaceutics-ceo-dr-issa-odidi-preventing-overdose-death-oxycodone-fentanyl/
Here is an exact quote:
And then there are several combination products that are coming for opiates, these are based on our PODRAS technology, the abuse deterrent technology and the overdose technology. And then we are looking at several other once-a-day products with regards to hydromorphone,oxymorphone and hydrocodone. And like I said earlier, there are several more we haven’t made public, and therefore I won’t be able to talk about them.
When do you plan to inform shareholders about all these PODRAS based products you are working on? We have heard absolutely nothing in regards to these as well as PODRAS since the interview.
Sincerely,
Fabius- And why hasn't Odidi went out and purchased $100K of IPCI on the open market? If he believe in himself and his vision, put your IPCI loan interest money for one year on the line by buying shares on the open market.
Doog- Let's face it. Armistice got warrants. What would prevent them from short selling every share and driving the price down? Any offering with warrants is toxic. The investors don't believe in the company enough to put their money in without the warrants. So every time I see an offering with warrants, I know that there is potential for games to be played. Like Fabius says- these guys do not understand the financial markets... I agree. One of the last conversations I had with Penna was don't do an offering with warrants, those kill use. He agreed and said offerings with warrants are a last resort. I know you have been critical of Penna, but I do actually think he did as much as he could. I think it gets back to the point that Odidi just does not allow his employees to do their job. All I can think is that he is a horrible micro manager. Now do I know the guy and am I sure of this? No, but that is just the impression I get after watching this company since 2013. It seems like every decision down to toilet paper type has to go through Odidi. And if that is the case, that is one of the biggest problems with IPCI.
Doog- As of Oct 15, the HAP studies had not started and were scheduled to start within 30-60 days.
Fabius- Can't or won't???...
OK Angelo. I get the point. But I have seen it used to get info on buying things not partnering.
IPCI's window of opportunity for Regabatin is now. Fybromyalgia is not approved for Lyrica CR. Lets see if they can capitalize on this. Test results:
Phase I Clinical Trial
We successfully completed an initial Phase I clinical trial of a controlled-release pregabalin formulation. This was the first bioavailability study of our controlled-release pregabalin versus Lyrica® (immediate release pregabalin).
Phase I Clinical Trial Results
We conducted and analyzed the results of six Phase I clinical trials involving a twice-a-day formulation and a once-a-day formulation. For formulations directed to certain indications which include fibromyalgia, the results suggested that Regabatinâ„¢ 82.5 mg BID dosage was comparable in bioavailability to Lyrica® 50 mg (immediate-release pregabalin) TID dosage. For formulations directed to certain other indications which include neuropathic pain associated with diabetic peripheral neuropathy, the results suggested that Regabatinâ„¢ 165 mg once-a-day dosage was comparable in bioavailability to Lyrica® 75 mg BID dosage.
This is what new IPCI site says on Regabatin:
Regabatin: A New Solution Filling a Controlled Release Gap
Our once-a-day Regabatinâ„¢ (pregabalin) extended-release capsules are indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, spinal cord injury and fibromyalgia. Regabatinâ„¢ is based on our controlled release drug delivery technology platform which utilizes the symptomatology and chronobiology of fibromyalgia in a formulation intended to provide a higher exposure of pregabalin during the first 12 hours of dosing. Based on positive feedback and guidance from the FDA, we submitted an IND application for Regabatinâ„¢ in August 2015. The FDA completed its review of the IND application and provided constructive input that we will use towards further development of the program.
The brand reference drug is Lyrica® (immediate release pregabalin), and at the current time, there are no FDA approved controlled-release formulations on the market. A controlled-release version of pregabalin should reduce the number of doses patients take, potentially improving patient compliance and clinical outcomes.
Looks like they are touting for fibromyalgia as Pfizer did not get approval for that indication. Now lets see if anyone bites...
Become a partner with IPCI... Has anyone looked at the website? They are trying to get people to contact them through a forms page on their website to become partners... Is that really an effective way for a pharmaceutical technology companies to find partners? I really don't know, but my guess is no real partners for Rexista and Regabatin would actually fill that in. Anyone have an opinion here? Tilator?
Doog- it is absolutely mind boggling at how bad things have went for IPCI. They just cannot catch a break or possibly management is just so poor and slow moving they cannot and will not respond accordingly to just about every curveball that is thrown.
mopar- that is certainly good news. Lets hope they keep increasing positions as well as other institutions come in.
Fabius- those guys are definitely 100% here! absolutely no doubt.
Tilator- Some people/analyst were calling for ridiculously high IPCI revenue for Seroquel. I was the pessimist calling for $3M per quarter. I am pretty sure we are not going to see my estimate any time soon. There has just been one disappointment and delay with IPCI's cash flow positive status after another. In 2014, Focalin XR was supposed to bring IPCI to that level. But TEVA delayed launch of those doses and eventually the FDA pulled IPCI's tentative approval for the other doses. Sadly, we did not start seeing that additional Focalin dose revenue until 2017. 2017 was then supposed to be the game changer. But PAR's delays in launching the other doses coupled with MNK's weak Seroquel launch has us already at Q4 2017 and shareholders are dreaming of $2M in revenue for that quarter. That $2M will not be realized and even if it were, it is no where near a cash flow positive status. I know I sound like a broken record, but this company seems to have the worst luck.